Business Description
Moleculin Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US60855D1019
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 20.39 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 20.4 | |||||
3-Year EPS without NRI Growth Rate | 21.3 | |||||
3-Year FCF Growth Rate | 23.6 | |||||
3-Year Book Growth Rate | -20.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 26.14 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 31 | |||||
14-Day RSI | 37.34 | |||||
6-1 Month Momentum % | -14 | |||||
12-1 Month Momentum % | 26.47 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.39 | |||||
Quick Ratio | 2.39 | |||||
Cash Ratio | 1.89 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -42.5 | |||||
Shareholder Yield % | -59.75 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -89.39 | |||||
ROA % | -69.42 | |||||
ROIC % | -232.41 | |||||
3-Year ROIIC % | -10633.33 | |||||
ROC (Joel Greenblatt) % | -3860.76 | |||||
ROCE % | -90.69 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.35 | |||||
Price-to-Tangible-Book | 0.95 | |||||
EV-to-EBIT | 0.13 | |||||
EV-to-Forward-EBIT | -6.27 | |||||
EV-to-EBITDA | 0.13 | |||||
EV-to-Forward-EBITDA | -7.05 | |||||
EV-to-FCF | 0.14 | |||||
Price-to-Net-Current-Asset-Value | 1.06 | |||||
Price-to-Net-Cash | 2.09 | |||||
Earnings Yield (Greenblatt) % | 756.4 | |||||
FCF Yield % | -375.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Moleculin Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -10.917 | ||
Beta | 1.6 | ||
Volatility % | 70.28 | ||
14-Day RSI | 37.34 | ||
14-Day ATR (€) | 0.00003 | ||
20-Day SMA (€) | 6.45 | ||
12-1 Month Momentum % | 26.47 | ||
52-Week Range (€) | 5.039999 - 12.749999 | ||
Shares Outstanding (Mil) | 2.84 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Moleculin Biotech Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Moleculin Biotech Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Moleculin Biotech Inc Frequently Asked Questions
What is Moleculin Biotech Inc(FRA:MOL)'s stock price today?
When is next earnings date of Moleculin Biotech Inc(FRA:MOL)?
Does Moleculin Biotech Inc(FRA:MOL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |